$EDIT

Editas Medicine, Inc.

Editas Medicine is a gene editing company developing genomic medicines for serious diseases. Its proprietary CRISPR platform includes Cas9, Cas12a and engineered variants, along with guide RNA design and delivery technologies. The company focuses its research and development on in vivo gene editing, including medicines targeting liver cells, hematopoietic stem cells and other tissues. Its lead development candidate, EDIT-401, is designed to reduce LDL cholesterol by increasing expression of the LDL receptor. Editas is also developing an in vivo approach for sickle cell disease and transfusion-dependent beta thalassemia, and collaborates with partners on engineered T-cell therapies. It earns money through licensing its gene editing technology and intellectual property, and through collaboration agreements that can provide payments and royalties. Editas Medicine is headquartered in Cambridge, Massachusetts.

No enriched coverage for $EDIT in the last 7 days.

—
$70K
Burkly Linda
100%
See all $EDIT insider activity →
Med

Editas Medicine Plans Human Trial After Gene Therapy Slashed LDL 90% in Primate Study

Editas Medicine (NASDAQ:EDIT) plans human trials after its gene therapy reduced LDL cholesterol by 90% in primates. The company raised $125M, extending its cash runway to 2028. CFO Amy Parison said funds will support trial completion. CEO O'Neill noted potential approval path for LDL reduction, pending regulatory agreement.

Editas Medicine Reports Q3 2026 Results, $10.4M Revenue and $23.4M Net Loss

Editas Medicine reported Q3 2026 revenue of $10.4M and a net loss of $23.4M, improving from the same period last year. The company received Australian clearance for its Phase 1/2 Strive study of EDIT-401 and expects to dose the first patients this year. Editas anticipates its cash resources will fund operations into the second half of 2028. Preclinical data for EDIT-401 showed promising results in non-human primates.

Editas Medicine Announces Third Quarter 2026 Results and Business Updates

Editas Medicine, Inc. (EDIT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Editas Medicine Annou nces Third Quarter 2026 Results and Bu siness Updates Company received HREC approval to initiate Phase 1/2 Strive™ study of EDIT-401 in patients with hyperlipidemia in Australia New preclinical data presented at AHA Scientific Sessions demonstrating ≥90 perc

EDIT sentiment & insider activity

Recent EDIT coverage spans financial news, earnings and regulation.

In the last 30 days, EDIT insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($70K). The most active reporter was Burkly Linda, EVP, CHIEF SCIENTIFIC OFFICER, with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.

What's driving EDIT

AlphAI scores every news story that mentions EDIT with an AI model for sentiment and relevance, and aggregates insider trades from Editas Medicine, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $EDIT

Score

Editas Medicine Reports Q3 2026 Results, $10.4M Revenue and $23.4M Net Loss

Editas Medicine reported Q3 2026 revenue of $10.4M and a net loss of $23.4M, improving from the same period last year. The company received Australian clearance for its Phase 1/2 Strive study of EDIT-401 and expects to dose the first patients this year. Editas anticipates its cash resources will fund operations into the second half of 2028. Preclinical data for EDIT-401 showed promising results in non-human primates.

$EDITMedEarnings

Editas Medicine Announces Third Quarter 2026 Results and Business Updates

Editas Medicine, Inc. (EDIT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Editas Medicine Annou nces Third Quarter 2026 Results and Bu siness Updates Company received HREC approval to initiate Phase 1/2 Strive™ study of EDIT-401 in patients with hyperlipidemia in Australia New preclinical data presented at AHA Scientific Sessions demonstrating ≥90 perc

$PRMEHighAI 8/10

StockWatch: Gene Editing Shares Jump on ESGCT Data, FDA Draft Guidance

Shares of gene editing therapy companies surged this week due to positive data from the ESGCT Congress and FDA draft guidance for personalized gene therapies. Prime Medicine (PRME) rose 29%, Beam Therapeutics (BEAM) 13%, Editas Medicine (EDIT) 11%, and Intellia Therapeutics (NTLA) 11%. The FDA's guidance aims to streamline approvals for individualized genome editing products. Analysts view the developments positively, anticipating continued momentum.

$PRMEHighAI 8/10

PRME, BEAM, EDIT, NTLA, CRSP Stocks Gain As FDA Signals Faster Route For Patient-Specific Gene Edits

Shares of gene-editing companies, including Prime Medicine (PRME), Beam Therapeutics, Intellia Therapeutics (NTLA), Editas Medicine (EDIT), and CRISPR Therapeutics (CRSP), rose after the FDA issued draft guidance to expedite personalized treatments for rare genetic diseases. The new approach allows one application for multiple versions of the same gene-editing treatment. PRME gained 20%, with other companies seeing 4-14% increases.

$EDITMedAI 8/10

Wells Fargo Upgrades Editas Medicine (EDIT) on Phase 1/2 Trial A

Wells Fargo upgraded Editas Medicine (EDIT) to Overweight, raising its price target to $6 from $4. This follows the company's approval to start a Phase 1/2 trial for EDIT-401 in Australia, targeting a genetic condition. Editas has a P/S ratio of 6.15, below its historical median of 33.7x, and a GF Score of 51/100, indicating moderate fundamentals with weak profitability and financial strength.

CRSP, NTLA, BEAM, PRME, EDIT Shares Slip — Did Claude Just Spook Gene-Editing Stocks?

Gene-editing stocks fell Wednesday after Anthropic's AI model, Claude, identified a phage enzyme system with traits similar to CRISPR. CRISPR Therapeutics (CRSP) dropped 6%, Intellia (NTLA) 3%, Beam (BEAM) 6%, Prime Medicine (PRME) 12%, and Editas Medicine (EDIT) 8%. The discovery, called ART, links an RNA-to-DNA enzyme with repeating DNA and a mystery protein in bacteria-infecting viruses. CRISPR pioneer Feng Zhang called the finding intriguing but unproven.

Microsoft upgraded, HubSpot initiated: Wall Street's top analyst calls

Stifel upgraded Microsoft (MSFT) to Buy with a $575 price target, citing sustained revenue growth. Susquehanna upgraded RXO Inc. (RXO) to Neutral with a $19 target. JPMorgan upgraded Graphic Packaging (GPK) to Overweight with an $11.50 target. RBC upgraded Lakefront Biotherapeutics (LKFT) to Outperform with a $45 target. Guggenheim upgraded Editas Medicine (EDIT) to Buy with a $5 target. Wedbush downgraded Compass Therapeutics (CMPX) to Neutral with a $1 target.

Related tickers